Year: 2025

Operating Profit of $22 million, up 36.7% YoY, Operating Margin of 9.4% Double-digit growth in orders and sales Entering Second Half with $321 million of Product Backlog, up 36% from second quarter fiscal 2025 Ending Net Cash Balance of $138 million Business and Digital Transformation on Track; Reiterating Three Year Forward Objectives of 7-10% Sales Growth, 10-12% operating margin, 17-20% ROIC BROOKINGS, S.D., Dec. 10, 2025 (GLOBE NEWSWIRE) — Daktronics, Inc. (NASDAQ-DAKT) (the “Company”, “Daktronics”, “we”, or “us”), a recognized industry leader in the design and manufacturing of best-in-class dynamic video communication displays and control systems for customers worldwide, today reported results for its fiscal 2026 second quarter which ended November 1, 2025. Fiscal 2026 is a 53-week year and fiscal 2025 was a 52-week year....

Dragonfly Energy announces distribution partnership with National Railway Supply LLC (“NRS”), marking the first lithium battery line offered by the long-standing rail supplier. AREMA formally approves its first lithium battery standard, creating a clear framework for LiFePO₄ adoption; Dragonfly Energy contributed to the multi-year development process and adoption. NRS to feature Battle Born Batteries® at the AREMA Communication Signals and Information Technology Symposium in March 2026, where Dragonfly Energy CEO Dr. Denis Phares will also present on LiFePO₄ technology and standards.RENO, Nev., Dec. 10, 2025 (GLOBE NEWSWIRE) — Dragonfly Energy Holdings Corp. (Nasdaq: DFLI) (“Dragonfly Energy” or the “Company”), an industry leader in energy storage and maker of Battle Born Batteries®, announced a new distribution partnership...

MDNA11 demonstrates durable anti-tumor activity in phase-2 eligible expansion cohorts, enriched for immune checkpoint resistant melanoma, MSS endometrial cancer, MSI-H and TMB-H cancers, in each case exceeding objective response rate (ORR) benchmarks in these difficult to treat populations  In the monotherapy expansion cohorts, irrespective of tumor type, patients treated with MDNA11, as the next treatment following progression on immune checkpoint inhibitors (ICI), had an ORR of 42% and a disease control rate (DCR) of 83% underscoring potential of MDNA11 in earlier lines of treatment Monotherapy expansion cohorts demonstrate ORRs of 38% in melanoma and 22% in MSI-H corresponding to DCR of 75% and 78%, respectively MDNA11 in combination with KEYTRUDA (pembrolizumab) shows ORR and DCR of 50% and 75%, respectively, for MSS endometrial cancer...

Not for distribution to United States newswire services or for release, publication, distribution or dissemination, directly or indirectly, in whole or in part, in or into the United States. TORONTO, Dec. 10, 2025 (GLOBE NEWSWIRE) — Voyageur Mineral Explorers Corp. (“Voyageur”) (CSE: VOY) and Evolve Strategic Element Royalties Ltd. (“Evolve”) are pleased to announce that they have received conditional approval from the Canadian Securities Exchange (“CSE”) pursuant to CSE Policy 8 – Fundamental Changes and Changes of Business in connection with their previously-announced business combination (the “Business Combination”). “The CSE’s conditional approval is an important milestone in the launch of Evolve Royalties Ltd.,” said Joseph de la Plante, President and Chief Executive Officer. “Our upcoming listing will position Evolve to execute...

Results support the potential of PMN310 to improve outcomes by selectively targeting oligomers and avoiding binding to monomer and plaque  ProMIS on track to complete enrollment in PRECISE-AD trial in Alzheimer’s disease by end of 2025 with planned Q2 2026 interim readout Cambridge, Massachusetts, Dec. 10, 2025 (GLOBE NEWSWIRE) — ProMIS Neurosciences Inc. (Nasdaq: PMN), a clinical-stage biotechnology company focused on the generation and development of antibody therapeutics and vaccines targeting toxic misfolded proteins in neurodegenerative diseases, such as Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD), today announced a publication in the peer-reviewed journal Alzheimer’s & Dementia: Translational Research & Clinical Interventions. entitled, “Relationship between efficacy...

NEW YORK, Dec. 10, 2025 (GLOBE NEWSWIRE) — OTC Markets Group Inc. (OTCQX: OTCM), operator of regulated markets for trading 12,000 U.S. and international securities, today announced Vizsla Royalties Corp. (TSX-V: VROY; OTCQX: VROYF), a precious metals focused royalty company, has qualified to trade on the OTCQX® Best Market. Vizsla Royalties Corp. upgraded to OTCQX from the OTCQB® Venture Market. Vizsla Royalties Corp. begins trading today on OTCQX under the symbol “VROYF.” U.S. investors can find current financial disclosure and Real-Time Level 2 quotes for the company on www.otcmarkets.com. The OTCQX Market is designed for established, investor-focused U.S. and international companies. To qualify for OTCQX, companies must meet high financial standards, follow best practice corporate governance, and demonstrate compliance with...

Miami, FL, Dec. 10, 2025 (GLOBE NEWSWIRE) — Tecnoglass, Inc. (NYSE: TGLS) (“Tecnoglass” or the “Company”), a leading producer of high-end aluminum and vinyl windows and architectural glass for the global residential and commercial end markets, today announced that its Board of Directors has declared a quarterly dividend of $0.15 per share, or $0.60 per share on an annualized basis, for the fourth quarter of 2025. Shareholders of record as of the close of business on December 31, 2025 will be paid a dividend of $0.15 on January 30, 2026. About Tecnoglass Tecnoglass Inc. is a leading producer of high-end aluminum and vinyl windows and architectural glass serving the multi-family, single-family, and commercial end markets. Tecnoglass is the second largest glass fabricator serving the U.S. and the #1 architectural...

Contract is with contract manufacturer in key U.S. manufacturing hub MONTREAL, Dec. 10, 2025 (GLOBE NEWSWIRE) — PyroGenesis Inc. (“PyroGenesis”) (TSX: PYR) (OTCQX: PYRGF) (FRA: 8PY1), the leader in ultra-high temperature processes and engineering innovation, and a plasma-based technology provider to heavy industry & defense, announces today the recent signing of an initial order of “fine cut” titanium powder produced by PyroGenesis’ NexGen™ plasma atomization process. The customer is a contract manufacturer specializing in titanium-based additive manufacturing for the consumer product and healthcare industries. Following the announcement earlier this week [press release dated December 8, 2025] of a half tonne order for PyroGenesis’ “coarse” cut titanium powder, the contract announced today is for the supply of “fine”...

Test-Controls & Reference Materials for Labs & Test-Makers MISSISSAUGA, Ontario, Dec. 10, 2025 (GLOBE NEWSWIRE) — Microbix Biosystems Inc. (TSX: MBX, OTCQX: MBXBF, Microbix®), a life sciences innovator, manufacturer, and exporter, announces the commercial launch of QAPs™ quality assessment products and availability of QUANTDx™ reference materials to support antigen or molecular tests for H3N2 strains of seasonal Influenza A (a.k.a., the “Flu”). H3N2, alongside H1N1, is a common type of Influenza A that circulates annually, with H3N2 more prone to “antigenic drift,” changing the surface of the virus and its level of recognition by antibodies. These changes can reduce the level of protection natural immunity and vaccine-induced immunity normally provide. Additionally, antigenic drift may reduce the accuracy...